These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34625283)

  • 21. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
    Young JB; Gauthier-Loiselle M; Bailey RA; Manceur AM; Lefebvre P; Greenberg M; Lafeuille MH; Duh MS; Bookhart B; Wysham CH
    Cardiovasc Diabetol; 2018 Aug; 17(1):118. PubMed ID: 30143045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real-world study of patients followed for up to 19 years.
    Coles B; Zaccardi F; Hvid C; Davies MJ; Khunti K
    Diabetes Obes Metab; 2021 Jan; 23(1):218-227. PubMed ID: 33026165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
    Amin AN; Jhaveri M; Lin J
    Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman J; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Cardiovasc Diabetol; 2018 Apr; 17(1):54. PubMed ID: 29636104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk prediction model and stratification in patients with type 2 diabetes enrolled in a Medicare Advantage plan.
    Caplan EO; Hayden J; Pimple P; Luthra R; Prewitt T; Chiguluri V; Kattan MW; Goss A; Harvey R
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1579-1591. PubMed ID: 34714109
    [No Abstract]   [Full Text] [Related]  

  • 26. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients.
    Toth PP; Philip S; Hull M; Granowitz C
    Mayo Clin Proc; 2019 Sep; 94(9):1670-1680. PubMed ID: 31405751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of pre-existing type 2 diabetes with and without cardiovascular disease on patients with COVID-19.
    Nguyen C; Crowe CL; Kuti E; Narsipur N; Donato B; Pepe RS; Djaraher R; Seman L; Graeter N; Power TP; Mehra R; Willey VJ
    Diabetes Obes Metab; 2023 Sep; 25(9):2464-2472. PubMed ID: 36999236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing hospitalization or emergency department visits and mortality in type 2 diabetes following the onset of new cardiovascular diagnoses in a population-based study.
    Agvall B; Jonasson JM; Galozy A; Halling A
    Cardiovasc Diabetol; 2024 Apr; 23(1):124. PubMed ID: 38600574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis.
    Sattui SE; Rajan M; Lieber SB; Lui G; Sterling M; Curtis JR; Mandl LA; Navarro-Millán I
    Semin Arthritis Rheum; 2021 Feb; 51(1):292-298. PubMed ID: 33433365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases.
    Broder MS; Greene M; Chang E; Hartry A; Touya M; Munday J; Yan T
    Clin Ther; 2018 Oct; 40(10):1670-1682. PubMed ID: 30193748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining initial and follow-up costs of cardiovascular events in a US managed care population.
    Chapman RH; Liu LZ; Girase PG; Straka RJ
    BMC Cardiovasc Disord; 2011 Mar; 11():11. PubMed ID: 21410963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular disease prevalence in type 2 diabetes - an analysis of a large German statutory health insurance database.
    Gabler M; Geier S; Mayerhoff L; Rathmann W
    BMC Public Health; 2021 Feb; 21(1):328. PubMed ID: 33563256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population.
    Kern DM; Mellström C; Hunt PR; Tunceli O; Wu B; Westergaard M; Hammar N
    Curr Med Res Opin; 2016; 32(4):703-11. PubMed ID: 26709864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative measure of asymptomatic cardiovascular disease risk in Type 2 diabetes: Evidence from Indian outpatient setting.
    Ghosal S; Sinha B; Ved J; Biswas M
    Indian Heart J; 2020; 72(2):119-122. PubMed ID: 32534684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.
    Hallberg S; Gandra SR; Fox KM; Mesterton J; Banefelt J; Johansson G; Levin LÅ; Sobocki P
    Eur J Health Econ; 2016 Jun; 17(5):591-601. PubMed ID: 26077550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
    Jin Y; Kang EH; Brill G; Desai RJ; Kim SC
    J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies.
    Razquin C; Ruiz-Canela M; Clish CB; Li J; Toledo E; Dennis C; Liang L; Salas-Huetos A; Pierce KA; Guasch-Ferré M; Corella D; Ros E; Estruch R; Gómez-Gracia E; Fitó M; Lapetra J; Romaguera D; Alonso-Gómez A; Serra-Majem L; Salas-Salvadó J; Hu FB; Martínez-González MA
    Cardiovasc Diabetol; 2019 Nov; 18(1):151. PubMed ID: 31722714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
    Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
    J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
    Shah M; Butler M; Bramley T; Curtice TG; Fine S
    Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.